Protagonist Therapeutics Inc. (PTGX) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Protagonist Therapeutics Inc. (PTGX) carries a Roarable Rating of C (Hold) with 65/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
How PTGX Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $4.00B | 0% | -4% | -$130.1M | $56.1M | -24.5% |
| FY 2024 | $4.00B | 0% | 6.3% | $275.2M | $182.8M | 32.8% |
| FY 2023 | $4.00B | 0% | -2.3% | -$79.0M | -$70.2M | -2.4% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring PTGX)
- ✓Live walkthrough of PTGX's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
PTGX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. 0.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on PTGX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for PTGX. Explore sector supply chains on /butterfly.
PTGX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Protagonist Therapeutics Inc. (PTGX)?
In FY 2025 (10-K), PTGX converted $4.0B of revenue into a 0% gross margin, 0% operating margin, and $56.1M in free cash flow (1.4% FCF margin).